MX2022015435A - Derivados de quinoxalina como farmacos anti-cancer. - Google Patents

Derivados de quinoxalina como farmacos anti-cancer.

Info

Publication number
MX2022015435A
MX2022015435A MX2022015435A MX2022015435A MX2022015435A MX 2022015435 A MX2022015435 A MX 2022015435A MX 2022015435 A MX2022015435 A MX 2022015435A MX 2022015435 A MX2022015435 A MX 2022015435A MX 2022015435 A MX2022015435 A MX 2022015435A
Authority
MX
Mexico
Prior art keywords
cancer drugs
quinoxaline derivatives
quinoxaline
derivatives
drugs
Prior art date
Application number
MX2022015435A
Other languages
English (en)
Inventor
Xiaolan Zheng
Martin John Packer
Sebastien Louis Degorce
Jeffrey Wallace Johannes
Sudhir Mahadeo Hande
Avipsa Ghosh
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2022015435A publication Critical patent/MX2022015435A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención se refiere a compuestos de azaquinolona de Fórmula (I), y a su uso en medicina. (ver Fórmula) Fórmula (I).
MX2022015435A 2020-06-25 2021-06-24 Derivados de quinoxalina como farmacos anti-cancer. MX2022015435A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063044095P 2020-06-25 2020-06-25
US202063120351P 2020-12-02 2020-12-02
PCT/EP2021/067304 WO2021260092A1 (en) 2020-06-25 2021-06-24 Quinoxaline derivatives as anti-cancer drugs

Publications (1)

Publication Number Publication Date
MX2022015435A true MX2022015435A (es) 2023-02-09

Family

ID=76662494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015435A MX2022015435A (es) 2020-06-25 2021-06-24 Derivados de quinoxalina como farmacos anti-cancer.

Country Status (19)

Country Link
US (2) US11795158B2 (es)
EP (1) EP4172152A1 (es)
JP (1) JP2023532257A (es)
KR (1) KR20230026450A (es)
CN (1) CN115768760A (es)
AU (1) AU2021295423B2 (es)
BR (1) BR112022025435A2 (es)
CA (1) CA3186996A1 (es)
CL (1) CL2022003711A1 (es)
CO (1) CO2023000186A2 (es)
CR (1) CR20230024A (es)
DO (1) DOP2022000288A (es)
EC (1) ECSP23005059A (es)
IL (1) IL299123A (es)
MX (1) MX2022015435A (es)
PE (1) PE20231081A1 (es)
TW (1) TW202218664A (es)
UY (1) UY39296A (es)
WO (1) WO2021260092A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220040173A1 (en) * 2020-08-04 2022-02-10 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer
WO2022225934A1 (en) 2021-04-19 2022-10-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
AU2022280845A1 (en) 2021-05-24 2023-12-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
EP4355334A1 (en) * 2021-06-16 2024-04-24 Repare Therapeutics Inc. Use of atr inhibitors in combination with parp inhibitors for treating cancer
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023046158A1 (zh) * 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
WO2023051807A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 双环衍生物parp抑制剂及其用途
US20230159525A1 (en) 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
WO2023118085A1 (en) * 2021-12-21 2023-06-29 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
CN116425744A (zh) * 2022-01-13 2023-07-14 优领医药科技(香港)有限公司 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用
WO2023138541A1 (zh) * 2022-01-20 2023-07-27 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
US11939329B2 (en) 2022-01-21 2024-03-26 Xinthera, Inc. PARP1 inhibitors and uses thereof
WO2023146957A1 (en) * 2022-01-27 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
WO2023146960A1 (en) * 2022-01-28 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
TW202400596A (zh) * 2022-04-28 2024-01-01 美商辛瑟拉股份有限公司 三環parp1抑制劑及其用途
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
WO2023217045A1 (zh) * 2022-05-07 2023-11-16 南京明德新药研发有限公司 选择性抑制parp1的氟代喹喔啉酮衍生物
WO2023227052A1 (zh) * 2022-05-25 2023-11-30 西藏海思科制药有限公司 双环衍生物parp抑制剂及其用途
WO2023232069A1 (zh) * 2022-06-02 2023-12-07 成都苑东生物制药股份有限公司 一种氮杂喹啉酮类衍生物、其制备方法及用途
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer
CN115919859B (zh) * 2022-07-14 2024-01-05 四川海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
WO2024067691A1 (zh) * 2022-09-30 2024-04-04 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
WO2024077137A1 (en) * 2022-10-06 2024-04-11 Xinthera, Inc. Crystalline forms of a parp1 inhibitor
WO2024083218A1 (zh) * 2022-10-20 2024-04-25 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503943A (ja) 1994-08-12 2002-02-05 ミリアド・ジェネティックス・インコーポレイテッド １７ｑ−連鎖乳癌および卵巣癌感受性遺伝子におけるイン・ビボ突然変異および多形性
ES2154712T5 (es) 1994-08-12 2009-12-14 The University Of Utah Research Foundation Metodo para diagnosticar la predisposicion al cancer de mama y de ovarios.
CA2517629C (en) 2003-03-12 2011-07-12 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
KR101779137B1 (ko) 2009-01-23 2017-09-18 다케다 야쿠힌 고교 가부시키가이샤 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제
NZ738187A (en) 2015-06-09 2019-03-29 Je Il Pharmaceutical Co Ltd Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
AU2020318599B2 (en) 2019-07-19 2023-09-07 Astrazeneca Ab PARP1 inhibitors

Also Published As

Publication number Publication date
CO2023000186A2 (es) 2023-04-17
UY39296A (es) 2021-12-31
US20220009901A1 (en) 2022-01-13
EP4172152A1 (en) 2023-05-03
CN115768760A (zh) 2023-03-07
TW202218664A (zh) 2022-05-16
IL299123A (en) 2023-02-01
PE20231081A1 (es) 2023-07-17
BR112022025435A2 (pt) 2023-01-24
US20240010631A1 (en) 2024-01-11
JP2023532257A (ja) 2023-07-27
CL2022003711A1 (es) 2023-06-23
AU2021295423A1 (en) 2023-02-16
WO2021260092A1 (en) 2021-12-30
AU2021295423B2 (en) 2024-05-02
CR20230024A (es) 2023-03-01
ECSP23005059A (es) 2023-02-28
CA3186996A1 (en) 2021-12-30
KR20230026450A (ko) 2023-02-24
US11795158B2 (en) 2023-10-24
DOP2022000288A (es) 2023-01-15

Similar Documents

Publication Publication Date Title
AU2021295423B2 (en) Quinoxaline derivatives as anti-cancer drugs
JOP20220008A1 (ar) مثبطات parp1
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MD4584B1 (ro) (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1ʹ,2ʹ:4,5]pirazino[2,1-b][1,3]oxazepin-8-olat de sodiu
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
TR201819138T4 (tr) FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri
NZ733174A (en) Quinazoline derivatives used to treat hiv
NZ710854A (en) Quinolines derivatives as novel anticancer agents
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
MX2013003635A (es) Compuestos de n-heteroarilo.
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
EP4342473A3 (en) Compounds useful in hiv therapy
PH12018500378B1 (en) Novel annelated phenoxyacetamides
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2011013869A (es) Agentes antihelminticos y su uso.
SA520412155B1 (ar) مشتقات إيميدازوبيريدين واستخدامها كدواء
MX2012007172A (es) Piperazinas como agentes antimalaria.
MX2018015707A (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta.
MX2023000198A (es) Inhibidores de atr y usos de estos.
WO2018178497A3 (es) Uso de melatonina para el tratamiento de tumores
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.